Table 3.
Effect of CK2 inhibition on mitochondrial Ca2+ levels
Time in min | Drug (concentration in μM) | Mitochondrial Ca2+ level relative to pre-treatment Mean ± SD (p) | ||
---|---|---|---|---|
PC3-LN4 | C4–2B | 22Rv1 | ||
0 | DMSO | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 |
TBB (80) | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | |
TBB (40) | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | |
TBB (20) | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | |
CX-4945 (10) | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | |
RU360 (10) | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | |
5 | DMSO | 0.97 ± 0.04 | 1.03 ± 0.04 | 1.00 ± 0.00 |
TBB (80) | 1.30 ± 0.02** | 1.14 ± 0.03* | 1.30 ± 0.06*** | |
TBB (40) | 1.15 ± 0.16 | 1.04 ± 0.02 | 1.22 ± 0.07*** | |
TBB (20) | 1.20 ± 0.13 | 1.09 ± 0.05 | 1.11 ± 0.03# | |
CX-4945 (10) | 1.06 ± 0.13 | 1.11 ± 0.03# | 1.07 ± 0.02 | |
RU360 (10) | 1.05 ± 0.03 | 1.00 ± 0.01 | 1.00 ± 0.01 | |
10 | DMSO | 0.90 ± 0.02 | 1.04 ± 0.05 | 0.96 ± 0.05 |
TBB (80) | 1.34 ± 0.11*** | 1.28 ± 0.03*** | 1.23 ± 0.03*** | |
TBB (40) | 1.22 ± 0.09# | 1.16 ± 0.03* | 1.22 ± 0.05*** | |
TBB (20) | 1.39 ± 0.04*** | 1.12 ± 0.04 | 1.21 ± 0.03*** | |
CX-4945 (10) | 1.10 ± 0.10* | 1.15 ± 0.04* | 1.15 ± 0.04*** | |
RU360 (10) | 1.04 ± 0.01 | 1.00 ± 0.01 | 1.01 ± 0.01 | |
15 | DMSO | 0.97 ± 0.03 | 1.03 ± 0.02 | 0.99 ± 0.01 |
TBB (80) | 1.50 ± 0.09*** | 1.29 ± 0.04*** | 1.30 ± 0.06*** | |
TBB (40) | 1.29 ± 0.07*** | 1.14 ± 0.06# | 1.20 ± 0.03*** | |
TBB (20) | 1.37 ± 0.10*** | 1.19 ± 0.03** | 1.12 ± 0.05* | |
CX-4945 (10) | 1.17 ± 0.11# | 1.19 ± 0.04** | 1.07 ± 0.04 | |
RU360 (10) | 1.06 ± 0.03 | 1.02 ± 0.04 | 1.03 ± 0.01 |
Ca2+ levels represent the change within the treatment condition relative to pre-treatment of cells with the various agents shown in the drug column. DMSO served as vehicle control while RU360 served as control inhibiting Ca2+ import into mitochondria. Mean and standard deviation are listed with p values included in parentheses:
p < 0.1;
p < 0.05;
p < 0.01;
p < 0.001